What Is Solid-Phase Peptide Synthesis (SPPS)? The Method That Builds Almost Every Peptide

Published October 2026 · Patriot Labs Research Team · ~22 min read

The short answer

Solid-phase peptide synthesis (SPPS) is the standard chemical method for building a peptide one amino acid at a time on tiny insoluble resin beads. The growing chain stays anchored to the bead while reagents are washed in and out, so the peptide is assembled from its C-terminus toward its N-terminus and cut free only at the very end.

The trick that makes SPPS work is physical, not chemical. Because the peptide is tethered to a solid bead that does not dissolve, every excess reagent and by-product can be flushed away by simple filtration and washing after each step, rather than purified out of solution. That single change turned peptide assembly from a months-long sequence of isolations into a repeating, automatable cycle, and it is the reason almost every short and medium-length synthetic peptide made today — research-catalogue compounds included — is built this way. SPPS is one of the two industrial routes to a peptide; the other, growing it in engineered cells, is covered in Recombinant vs Synthetic Peptides, and the whole manufacturing picture in How Peptides Are Made. This guide is about the chemistry of the synthetic route itself.

Why building a peptide is hard

Making a peptide bond is easy; making the right peptide bond, in the right place, over and over, is not. Every amino acid carries both an amine group and a carboxyl group, and left to themselves they will react with one another in every possible combination. The difficulty of peptide synthesis is almost entirely a problem of control.

To join two amino acids in a defined order, a chemist has to block the groups that should not react and activate only the two that should. An amino acid has a reactive amine at one end (the N-terminus) and a reactive carboxyl at the other (the C-terminus), and many also have reactive side chains — the acids, amines, alcohols and thiols on residues such as aspartate, lysine, serine and cysteine. Before coupling, the amine that is not meant to react is capped with a temporary protecting group, the side chains are capped with more durable ones, and only then is the free carboxyl of the incoming residue chemically activated so it will attack the one free amine on the chain.^[1] An introductory account of this logic, and why it raises coupling yields from under a quarter to well above ninety per cent, is given in general treatments of peptide synthesis.^[2]

In classical solution-phase chemistry, this had to be done one isolated step at a time. After each coupling the intermediate peptide was purified, characterised and carried into the next reaction. Yields compounded unforgivingly: a chain of modest length could take the better part of a year, and the final yield could fall into the single digits. The method worked — the nine-residue hormones oxytocin and vasopressin were made in solution in the 1950s — but it did not scale to the longer sequences chemists wanted to reach. For the basic vocabulary of amino acids, peptide bonds and sequence, see What Are Peptides?

Merrifield’s idea: build it on a bead

The breakthrough was to stop isolating the intermediates at all. In 1963 Robert Bruce Merrifield, working at the Rockefeller Institute, published a short paper in the Journal of the American Chemical Society describing the synthesis of a tetrapeptide while the chain remained covalently attached to an insoluble polymer support.^[3]

His insight was that if the first amino acid were anchored to a bead of cross-linked polystyrene, the chain could be extended while still bound, and every clean-up step would reduce to washing the beads. Reagents could be used in large excess to drive each coupling toward completion, then simply rinsed away; nothing had to be recrystallised or chromatographed between residues. Merrifield had, by his own account, conceived the idea in 1959 and spent several years proving it. The method eliminated the intermediate isolations that made solution-phase synthesis so slow, and it was soon automated: a few years later his laboratory used a purpose-built machine to assemble the 124-residue enzyme ribonuclease A through thousands of programmed operations, a demonstration that would have been unthinkable by the older route.^[4] Merrifield received the 1984 Nobel Prize in Chemistry for the development of methodology for chemical synthesis on a solid matrix.^[5]

The principle has not changed in sixty years, even as almost every reagent has. The chain is still built on a bead; the beads are still washed between steps; the synthesis still runs from the C-terminus toward the N-terminus, the opposite direction to how a ribosome builds a protein in the cell. What changed was the protecting-group chemistry, and that change defines the two dialects of SPPS in use today.

The SPPS cycle, step by step

SPPS is a loop: deprotect, wash, couple, wash, and repeat once for every residue. The same handful of operations is performed again and again, which is exactly why the method lends itself to automation.

A single cycle, as set out in standard protocols, runs as follows.^[6] The resin is first swollen in solvent so reagents can reach the chain ends buried inside each bead. The temporary protecting group on the exposed N-terminus is then removed (deprotection), uncovering a single free amine. The beads are washed. The next amino acid — its own N-terminus still protected, its side chain still protected, its carboxyl activated by a coupling reagent — is added, and its activated carboxyl forms an amide bond with the free amine (coupling). The beads are washed again, and the cycle repeats with the next residue in the sequence. Many protocols add a brief capping step after coupling, in which any chains that failed to react are acetylated so they cannot be extended further; this stops a one-residue-short “deletion” chain from continuing and becoming a hard-to-separate impurity later.

Because each residue is added in large excess and washed away when done, individual couplings routinely exceed 99% completion — but that figure is also the method’s hidden arithmetic. At 99% per coupling, a 50-residue peptide retains only about 0.99⁴⁹, or roughly 61%, of chains as the full-length product; the rest carry at least one deletion. This compounding of small imperfections is the central reason SPPS gets harder as sequences get longer, and why the purification and analysis that follow synthesis matter as much as the assembly itself.

Two chemistries: Fmoc and Boc

SPPS comes in two main flavours, named for the temporary group used to protect the N-terminus: Boc and Fmoc. They differ in how that group is removed, and that one difference ripples through the whole process.

The original Merrifield method used the tert-butyloxycarbonyl (Boc) group, which is removed with acid — typically trifluoroacetic acid — at every cycle. Because the side-chain protecting groups and the resin link also have to survive repeated acid treatment, they are chosen to be even more acid-stable, and the finished peptide is finally cut from the resin with a much stronger acid, anhydrous hydrogen fluoride. HF is highly hazardous and demands specialised apparatus, which limited Boc chemistry’s spread outside dedicated laboratories.

The alternative, now dominant, chemistry uses the 9-fluorenylmethoxycarbonyl (Fmoc) group, introduced as a base-labile amino-protecting group by Carpino and Han in the early 1970s.^[7] Fmoc is removed not with acid but with a mild base — a solution of piperidine in the reaction solvent — which abstracts a proton and triggers elimination to release the chain’s free amine and a dibenzofulvene by-product that is washed away. Because deprotection is basic, the side-chain groups and resin linker can be made acid-labile instead, so the final peptide is released under comparatively mild acid (trifluoroacetic acid) with no need for HF.^[8] This “orthogonality” — base to remove the temporary group each cycle, acid to remove everything else at the end — is what made Fmoc SPPS safe and routine enough to put in a benchtop synthesizer, and it is the chemistry behind the great majority of peptides made today.

The resin and the linker

The resin is where the whole synthesis hangs, and the small molecule that joins the peptide to the bead — the linker — decides both how the chain comes off at the end and what chemical group the finished C-terminus will carry. Choosing the resin is therefore a decision about the product, not just the process.

The support itself is usually a bead of polystyrene lightly cross-linked with divinylbenzene, swollen in an organic solvent so that the reactive sites inside each bead become accessible; newer polyethylene-glycol-based supports improve swelling for difficult chains. The linker chemistry then determines the outcome.^[9] The original Merrifield resin attaches the chain through a benzyl ester and needs strong acid to release it, giving a C-terminal acid. Wang resin, standard in Fmoc work, also gives a C-terminal acid but releases under the milder trifluoroacetic acid used for Fmoc cleavage. Rink amide resin gives a C-terminal amide — the form many natural signalling peptides take — again under mild acid. The 2-chlorotrityl chloride resin is so acid-labile that the peptide can be removed with as little as 1% acid, mild enough to lift off a fully side-chain-protected fragment intact, which is what makes it the resin of choice for building protected pieces that will later be joined together, and for many cyclic peptides, discussed in Cyclic Peptides Explained.

Making the bond: coupling reagents

An amine and a carboxyl do not spontaneously form an amide at room temperature; the carboxyl has to be chemically activated first, and the reagent that does this is the single biggest lever on the speed, yield and stereochemical cleanliness of a synthesis. Decades of work have gone into better coupling reagents, and the choice is far from cosmetic.

The earliest activators were carbodiimides such as dicyclohexylcarbodiimide (DCC), which convert the carboxyl into a reactive intermediate that the amine can attack.^[2] Carbodiimides are usually paired with an additive — HOBt or the more reactive HOAt, introduced by Carpino — that intercepts the activated acid as a less reactive but more selective ester, which both speeds the coupling and suppresses racemisation, the unwanted scrambling of a residue’s stereochemistry.^[10] Modern automated synthesis more often uses the so-called onium salts, the uronium and phosphonium reagents such as HBTU, HATU, PyBOP and the newer, safer COMU, which activate the carboxyl and deliver the same stabilising additive in a single step. A 2011 review catalogued the proliferation so thoroughly that its title called the field “more than a letter soup.”^[11] The practical point for a reader is that the reagent choice is a trade-off between coupling speed, cost, safety and how well it protects the growing chain from racemisation — and that the same sequence made with different reagents can leave behind different impurity profiles.

Coming off the bead: cleavage

At the end of the assembly the peptide is still tethered to the resin and still wearing all of its side-chain protecting groups. A single final step, cleavage, usually removes both at once.

In Fmoc chemistry the standard cleavage reagent is concentrated trifluoroacetic acid, which severs the acid-labile linker and strips the acid-labile side-chain groups together, releasing the free peptide into solution. The reaction generates a cloud of reactive cationic fragments from the departing protecting groups, and these can re-attack vulnerable residues — tryptophan, methionine, cysteine, tyrosine — and damage the product. To prevent that, scavengers such as water, triisopropylsilane and 1,2-ethanedithiol are added to the cleavage cocktail to mop up the cations before they do harm; well-known recipes exist for different sequences.^[9] The peptide is then precipitated out of the acid, typically into cold ether, washed, and taken forward to purification. Trifluoroacetic acid at this stage is also one reason so many peptides end up as a TFA salt, a counterion question explored in TFA vs Acetate in Peptides.

What leaves the resin is crude peptide — the target sequence mixed with the deletion chains, incompletely deprotected species and side-reaction products that accumulated along the way. It is almost never used as is. The crude is purified, usually by preparative reversed-phase high-performance liquid chromatography (HPLC), and then freeze-dried to a stable powder, a step explained in What Is Lyophilization? Purity grades and what a percentage figure does and does not mean are covered in Peptide Purity Grades Explained.

Difficult sequences and the length limit

SPPS is not uniformly easy across all sequences; some are notoriously hard, and the difficulty usually comes from the growing chain folding or clumping on the bead so that reagents can no longer reach its end. These “difficult sequences” are a recognised problem with recognised fixes.

As a chain grows, stretches rich in certain residues can hydrogen-bond into sheet-like structures or aggregate on the resin, physically shielding the reactive N-terminus and causing couplings and deprotections to stall. The result is a rash of deletion products and a falling yield.^[6][12] Chemists counter this in several ways: by inserting temporary backbone-protecting groups (such as Dmb or Hmb) or pseudoproline dipeptides that kink the chain and break up the aggregation, by heating the reaction — microwave-assisted SPPS is now common — and by choosing resins and solvents that keep the chain better solvated. A second, chemically specific headache is aspartimide formation, a side reaction at aspartate residues under the repeated base treatment of Fmoc chemistry, which is suppressed with specialised protecting groups and modified deprotection conditions.

Even with these tools, there is a practical ceiling. Routine SPPS is generally reliable up to roughly 50 residues; beyond that, the compounding of small per-step losses and the growing risk of aggregation make a single continuous synthesis progressively harder and lower-yielding. Reaching true protein length by stepwise SPPS alone is possible but exacting — which is why, for longer targets, chemists turn to a different strategy entirely.

Past the limit: ligation and flow

Two developments pushed chemical synthesis past the length ceiling: a way to stitch finished pieces together, and a way to run the cycle far faster. Both start from SPPS rather than replacing it.

The first is native chemical ligation, reported by Dawson, Muir, Clark-Lewis and Kent in 1994. It joins two unprotected synthetic peptides in water: one piece ends in a thioester, the other begins with a cysteine, and they react selectively to form a normal peptide bond at the junction.^[13] Because each piece can be made comfortably by SPPS within the reliable length range and then ligated, native chemical ligation opened the door to the total chemical synthesis of small proteins — a workaround for the length limit rather than a repeal of it.

The second is speed. In 2020 a team led by Bradley Pentelute at MIT described a fully automated fast-flow synthesizer that adds each amino acid in about 2.5 minutes by pumping reagents continuously through a heated column of resin, and used it to make single-chain polypeptides up to 164 residues long, producing several synthetic proteins whose mass and, where tested, function matched their ribosome-made counterparts.^[14] Flow chemistry does not change the underlying deprotect-couple cycle; it just performs it in minutes rather than hours, and it points to where automated synthesis is heading.

From a bench column to a factory reactor

The same chemistry that runs on a few grams of resin in a benchtop synthesizer also runs in stirred reactors holding thousands of litres, and the recent boom in peptide medicines has driven a historic expansion of that large-scale capacity. The principle is identical; only the engineering differs.

At manufacturing scale, SPPS is performed in large jacketed reactors where resin is suspended, reagents are pumped in and out, and the same wash-deprotect-couple cycle is automated and controlled to pharmaceutical standards. Contract manufacturers now describe individual solid-phase reactors measured in thousands to tens of thousands of litres, and the total installed capacity has grown rapidly in response to demand for GLP-1 and other peptide drugs; the companies, locations and figures behind that build-out are set out in How Peptides Are Made and Where Are Peptides Made? Scale brings its own chemistry problems — above all the sheer volume of solvent. Standard SPPS runs in dipolar aprotic solvents such as dimethylformamide (DMF) and N-methylpyrrolidone, which are under increasing regulatory pressure on health and environmental grounds, and a substantial research effort is now aimed at greener solvents and reagents; one 2021 study, for example, showed that replacing piperidine with pyrrolidine for Fmoc removal widened the range of safer solvents that could be used.^[15] Green-chemistry concerns have become a central theme of modern process development precisely because peptide manufacturing is now so large.

What SPPS leaves behind, and why testing matters

No synthesis is perfect, and SPPS leaves a characteristic set of by-products that purification reduces but rarely eliminates entirely. Knowing what those by-products are is the reason analytical testing is central to peptide quality.

The commonest SPPS-related impurities follow directly from the chemistry described above: deletion sequences missing one or more residues from incomplete couplings; truncated chains; incompletely deprotected species still carrying a side-chain group; and products of side reactions such as aspartimide formation, oxidation or racemisation. The counterion left from cleavage and purification — often trifluoroacetate — and residual solvent are also part of what ends up in the vial. Many of these differ from the target by only a small mass, which is exactly why identity and purity have to be measured rather than assumed. The two routine tests are reversed-phase HPLC, which separates the target from closely related impurities and reports a purity percentage, and mass spectrometry, which confirms the molecular mass and so the identity of the chain. What those tests do and do not prove is the subject of Understanding Peptide COA Testing, and the broader chemistry of how finished peptides break down afterward is covered in How Peptides Degrade.

For reference, Patriot Labs is a first-responder-owned, US-based company, and every batch it sells is tested by an independent US laboratory by HPLC and mass spectrometry, with the certificate of analysis published on the product page — the same two measurements this section describes as the standard check on any synthetic peptide.

What this guide does not establish

This guide explains how peptides are chemically assembled. It does not describe what any peptide does, how any compound should be handled or used, or the origin of any particular product.

• It describes chemistry, not biology. Nothing here concerns what any peptide does in a cell, an animal or a person; the synthesis route is independent of any such question.
• It is general, not product-specific. The resins, reagents and conditions named are illustrative of the field. This guide makes no claim about the method, reagents, purity or synthesis location of any specific product.
• Chain-length figures are rules of thumb. The ~50-residue ceiling and per-coupling yields are typical values that vary widely with sequence, chemistry and equipment.
• It is not a protocol. The steps are described to explain the method, not to be followed; actual synthesis requires specialised training, reagents and apparatus.
• Manufacturing figures live elsewhere and change quickly. Capacity and company details are covered, with sources, in the companion manufacturing guides and are current only as of their writing.

Frequently asked questions

What is solid-phase peptide synthesis?

Solid-phase peptide synthesis (SPPS) is the standard chemical method for building a peptide one amino acid at a time on tiny insoluble resin beads. The growing chain stays anchored to the bead while reagents are washed in and out, so the peptide is assembled from its C-terminus toward its N-terminus and cut free only at the end. It is the route behind almost all short and medium-length synthetic peptides.

How does solid-phase peptide synthesis work?

It runs as a repeating cycle. The first amino acid is anchored to a resin bead; then, for each residue, the temporary protecting group on the chain’s exposed amine is removed, the beads are washed, the next protected and activated amino acid is coupled on, and the beads are washed again. The cycle repeats once per residue, and a single final cleavage step cuts the finished peptide off the resin and removes the side-chain protecting groups.

Who invented solid-phase peptide synthesis?

Robert Bruce Merrifield, at the Rockefeller Institute, who published the method in 1963 and received the 1984 Nobel Prize in Chemistry for developing chemical synthesis on a solid matrix. The core idea — building the chain while it stays attached to an insoluble bead so that purification becomes simple washing — has not changed since.

What is the difference between Fmoc and Boc SPPS?

They differ in the temporary group used to protect the chain’s amine and how it is removed each cycle. Boc chemistry removes the group with acid and requires hazardous anhydrous HF for the final cleavage. Fmoc chemistry removes the group with a mild base (piperidine) and uses comparatively mild trifluoroacetic acid for final cleavage, which made it safe to automate. Fmoc is the dominant method today.

Why are peptides made on a resin?

Because anchoring the chain to an insoluble bead turns every purification step into simple filtration and washing. Reagents can be used in large excess to push each coupling to completion, then rinsed away, instead of isolating and purifying the intermediate after every step as older solution-phase methods required. That is what made peptide assembly fast, repeatable and automatable.

How long a peptide can you make with SPPS?

Routine stepwise SPPS is generally reliable up to roughly 50 residues. Beyond that, small losses at each coupling compound and the growing chain tends to aggregate on the resin, lowering yield. Longer targets are usually reached by making shorter pieces and joining them — for example by native chemical ligation — or by newer fast-flow synthesizers that have assembled single chains over 160 residues long.

What is the difference between SPPS and recombinant peptide production?

SPPS builds a peptide chemically, one protected amino acid at a time on a resin. Recombinant production grows the peptide biologically, by expressing a synthetic gene in engineered microorganisms in a fermenter. Chemical synthesis handles short and chemically modified sequences well; recombinant expression suits longer, protein-like molecules. The trade-offs are compared in the guide Recombinant vs Synthetic Peptides.

Is solid-phase peptide synthesis used to make research peptides?

Yes. The great majority of short and medium-length synthetic research-catalogue peptides are made by Fmoc SPPS, typically by custom-synthesis laboratories running automated synthesizers, followed by HPLC purification and freeze-drying. The method itself says nothing about a given lot’s purity, which has to be demonstrated by lot-specific testing.

What impurities does SPPS leave behind?

Characteristic SPPS by-products include deletion sequences missing one or more residues, truncated chains, incompletely deprotected species, and side-reaction products such as aspartimides, along with residual counterion and solvent. Many differ from the target by only a small mass, which is why reversed-phase HPLC (for purity) and mass spectrometry (for identity) are the standard tests on a finished peptide.

References

1. Amblard, M., Fehrentz, J. A., Martinez, J., & Subra, G. (2006). Methods and Protocols of Modern Solid Phase Peptide Synthesis. Molecular Biotechnology, 33(3), 239–254. doi:10.1385/MB:33:3:239
2. Master Organic Chemistry. Introduction to Peptide Synthesis (2019). https://www.masterorganicchemistry.com/2019/02/15/introduction-to-peptide-synthesis/
3. Merrifield, R. B. (1963). Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide. Journal of the American Chemical Society, 85(14), 2149–2154. doi:10.1021/ja00897a025
4. Chemistry World. Merrifield’s resin (history of solid-phase peptide synthesis and the synthesis of ribonuclease A). https://www.chemistryworld.com/opinion/merrifields-resin/1017386.article
5. The Nobel Prize in Chemistry 1984 — Robert Bruce Merrifield, “for his development of methodology for chemical synthesis on a solid matrix.” NobelPrize.org. https://www.nobelprize.org/prizes/chemistry/1984/summary/
6. Coin, I., Beyermann, M., & Bienert, M. (2007). Solid-phase peptide synthesis: from standard procedures to the synthesis of difficult sequences. Nature Protocols, 2(12), 3247–3256. doi:10.1038/nprot.2007.454
7. Carpino, L. A., & Han, G. Y. (1972). 9-Fluorenylmethoxycarbonyl amino-protecting group. The Journal of Organic Chemistry, 37(22), 3404–3409. doi:10.1021/jo00795a005
8. Behrendt, R., White, P., & Offer, J. (2016). Advances in Fmoc solid-phase peptide synthesis. Journal of Peptide Science, 22(1), 4–27. doi:10.1002/psc.2836
9. ChemPep. Resins for Solid Phase Peptide Synthesis (resin and linker types, cleavage conditions and scavengers). https://chempep.com/resins-for-solid-phase-peptide-synthesis/
10. Carpino, L. A. (1993). 1-Hydroxy-7-azabenzotriazole. An efficient peptide coupling additive. Journal of the American Chemical Society, 115(10), 4397–4398. doi:10.1021/ja00063a082
11. El-Faham, A., & Albericio, F. (2011). Peptide Coupling Reagents, More than a Letter Soup. Chemical Reviews, 111(11), 6557–6602. doi:10.1021/cr100048w
12. Challenges and Perspectives in Chemical Synthesis of Highly Hydrophobic Peptides (2020). Frontiers in Chemistry / PMC7064641 (on-resin aggregation in difficult sequences). https://pmc.ncbi.nlm.nih.gov/articles/PMC7064641/
13. Dawson, P. E., Muir, T. W., Clark-Lewis, I., & Kent, S. B. H. (1994). Synthesis of Proteins by Native Chemical Ligation. Science, 266(5186), 776–779. doi:10.1126/science.7973629
14. Hartrampf, N., Saebi, A., Poskus, M., et al. (Pentelute, B. L.) (2020). Synthesis of proteins by automated flow chemistry. Science, 368(6494), 980–987. doi:10.1126/science.abb2491
15. Fmoc-Removal with Pyrrolidine Expands the Available Solvent Space in Green Solid-Phase Peptide Synthesis (2021). ACS Sustainable Chemistry & Engineering. doi:10.1021/acssuschemeng.1c04770

For more on the questions this guide touches, see How Peptides Are Made for the full manufacturing picture, Recombinant vs Synthetic Peptides for the biological alternative to chemical synthesis, Peptide Purity Grades Explained for what a purity figure means, Understanding Peptide COA Testing for how identity and purity are measured, and TFA vs Acetate in Peptides for the counterion left behind at cleavage.

All Patriot Labs products are sold strictly for in-vitro research and laboratory use only. Not for human or veterinary consumption. This guide is educational and describes how peptides are chemically synthesized in general terms; it is not medical advice, does not describe how to use any product, and makes no claim about the synthesis method or manufacturing location of any specific product.